Term
|
Definition
| SX, truama, immobility, Cancer, previous DVT, increasing age, pregnancy, estrogen, medical illness, heart/resp failure, obesity, smoking, varicose veins, central lines, inherited blood disorders |
|
|
Term
|
Definition
| (could be silent)Pain, tender, swelling, discoloration |
|
|
Term
|
Definition
| (could be silent)First sign may be death, resp. or cardiac symptoms, hemoptysis,pain |
|
|
Term
| Hospitalized pts at high risk for DVT |
|
Definition
| Critical care, spinal cord injury, major trauma, hip/knee surgery, stroke, general surgery, medical |
|
|
Term
| VTE risk levels & recommendations |
|
Definition
Low-Minor sx <40, no other risk factors
(early mobilization)
Moderate-minor sx,40-60,additional risk factors. (LDUH 5000u BID, LMWH, mechanical devices)
High->60, or 40-60 w/risk factors (LDUH 5000u TID, LMWH)
Highest-sx w/multi risk factors, ortho sx, major trauma (LMWH, fondaparinux, warfarin,or LDUH/LMWH + mechanical devices) |
|
|
Term
|
Definition
Used to reduce the ability of blood to clot.
-UFH, LMWH, oral anticoags, antiplatelets |
|
|
Term
Mechanical methods to prevent VTE
Benefit/problem |
|
Definition
Use has lack of bleeding potential
Has not shown to reduce risk of death or PE-has to be the right size
-use as adjunct, and in high bleed risk |
|
|
Term
|
Definition
| ASA, Plavix, Effient, Brilinta |
|
|
Term
|
Definition
Adjunct in revascularization.
Prevent thrombotic complications in-CAD, CHF, TIA, MI, PAD.
Prevent thrombotic complications in pts w/acute coronary syndrome, ST elevation MI after PCI |
|
|
Term
|
Definition
ASA-block prostaglandin synthesis preventing formation of thromboxane A2
Plavix-prevent fibrinogen binding at ADP receptors thus reducing platelet adhesion and aggregation, prodrug requires activation
Effient-same as plavix, occurs in rapid single step process |
|
|
Term
Antiplatelet-ASA
side effects |
|
Definition
| BLEEDING, edema, hyperglycemia, N/V, GI ulcers, renal failure, Reye's |
|
|
Term
Antiplatelet-Plavix
side effects |
|
Definition
| GI-pain, vomiting, dyspepsia, gastritis, constipation, HA, rash, pruritus, bleeding, arthralgia, URI, flu-like symptoms |
|
|
Term
Antiplatelet-Effient
side effects |
|
Definition
| BLEEDING-fatal, HTN, HA, hypercholesterolemia/hyperlipidemia, nausea, back pain, epistaxis |
|
|
Term
|
Definition
| other anticoags, NSAIDs, alcohol, ACE/ARB,antacids, diuretics |
|
|
Term
|
Definition
several CYP 450 subtrates, PPIs,
anticoags, NSAIDS, salicylates, platelet inhibitors, ginko |
|
|
Term
|
Definition
| Anticoags, ASA, heparin, LMWH, NSAIDs, G IIb/IIIa inhibitors, thrombolytic agents, several CYP 450 subtrates |
|
|
Term
|
Definition
| can be given rectal. 1/2 life 3h |
|
|
Term
|
Definition
| load dose, inhibition of aggregation begins in 2hrs, max effect 3-7days, 5days to return to baseline |
|
|
Term
|
Definition
| Load dose, inhibition of aggregation begins in 30min, max effect 3-5 days, return baseline 5-9days (irreversible binding) |
|
|
Term
|
Definition
| prevent thrombotic events in ACS. Block ADP receptors on the platelet surface. Reversible (effects wear off faster than Plavix or Effient) |
|
|
Term
|
Definition
| bleeding, dyspnea, HA, cough, dizzy, nausea, chest pain, diarrhea, ventricular pauses |
|
|
Term
|
Definition
| Factor Xa inhibitor. Selective |
|
|
Term
Xarelto
advantages over warfarin |
|
Definition
| set dose, rapid onset,lower bleeding risk, fewer interactions, no lab monitoring |
|
|
